Skip to main content
School of Public Health
block W logo University of Washington

Larry Kessler

faculty photo
Professor, Health Services
Adjunct Professor, Pharmacy


Education

ScD   Johns Hopkins University, 1978   (Health Services Admin)
BS   Boston University, 1973   (Mathematics)

Contact Info

email:   kesslerl@uw.edu

office:   F-351E, Health Sciences Building

address:
University of Washington
Department of Health Services
Seattle, WA 98195-3660

campus box:   357660
voice:   206-543-2703

About

Larry Kessler is a former Chair of the Department of Health Services. He served as Director of the Office of Surveillance and Biometrics, Center for Devices and Radiological Health, FDA until 2008. From 1984 to 1995, he headed and developed the Applied Research Branch at NCI. In 2001, he spent a year as a visiting scientist at the Fred Hutchinson Cancer Research Center and served on the faculty of the Department of Health Services.


Cost-effectiveness and diagnostic value of medical technology in screening for cancer and other diseases
  • HSERV 512
    Health Systems and Policy
  • HSERV 578
    Preparing, Writing, and Critiquing Scientific Research Proposals


Bartek MA, Kessler LG, Talbott JM, Nguyen J, Shalhub S. Washington State abdominal aortic aneurysm-related mortality shows a steady decline between 1996 and 2016. J Vasc Surg. 2019 Mar 5. pii: S0741-5214(19)30184-3. doi: 10.1016/j.jvs.2018.12.040. [Epub ahead of print]  PMID: 30850292
PubMed
 
DOI
 


Gold LS, Patrick DL, Hansen RN, Beckett V, Goss CH, Kessler L. Correspondence between symptoms and preference-based health status measures in the STOP study. J Cyst Fibros. 2018 Aug 28. pii: S1569-1993(18)30743-4. doi: 10.1016/j.jcf.2018.08.001. [Epub ahead of print]  PMID: 30170756
PubMed
 
DOI
 


Burnett-Hartman AN, Hua X, Rue TC, Golchin N, Kessler L, Rowhani-Rahbar A. Risk interval analysis of emergency room visits following colonoscopy in patients with inflammatory bowel disease. PLoS One. 2019 Jan 9;14(1):e0210262. doi: 10.1371/journal.pone.0210262. eCollection 2019.  PMID: 30625217    PMCID: PMC6326490
PubMed
 
PubMed Central
 
DOI
 


Thornblade LW, Mulligan MS, Odem-Davis K, Hwang B, Waworuntu RL, Wolff EM, Kessler L, Wood DE, Farjah F. Challenges in Predicting Recurrence after Resection of Node Negative Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Jul 19. pii: S0003-4975(18)31005-1. doi: 10.1016/j.athoracsur.2018.06.022. [Epub ahead of print]  PMID: 30031845    PMCID: PMC6347463
PubMed
 
PubMed Central
 
DOI
 


Farjah F, Kessler L. Rightsizing lung cancer surveillance. J Thorac Cardiovasc Surg. 2018 Oct 22. pii: S0022-5223(18)32803-4. doi: 10.1016/j.jtcvs.2018.10.046. [Epub ahead of print]  PMID: 30503741
PubMed
 
DOI
 


Institute of Translational Health Sciences UL
National Center for Advancing Translational Sciences (NCATS)
PI:   Disis           Dates:    3/1/2019 - 2/29/2020

Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial
Patient-Centered Outcomes Research Institute (PCORI)
PI:   Flum           Dates:    1/1/2019 - 12/31/2023

CISTO: Comparison of Intravesical therapy and Surgery as Treatment Options for Recurrent Bladder Cancer
Patient-Centered Outcomes Research Institute (PCORI)
PI:   Gore           Dates:    10/1/2018 - 12/31/2023

Reference Topic Number 0003: Rehabilitation of Patients with Kidney Failure: “Human Factors Considerations for the Ambulatory Kidney to Improve Vitality” (AKTIV)
US Department of Veterans Affairs (VA)
PI:   Kessler           Dates:    7/1/2018 - 6/30/2020

A Pivotal, Prospective, Three-Stage, Single-Arm Study of Focal Ablation of the Prostate with NanoTherm™ Therapy System for a Limited-Volume, Clinically Localized, Intermediate-Risk Prostate Cancer
MagForce USA, Inc.
PI:   Kessler           Dates:    7/1/2018 - 12/31/2019

Cost Effectiveness Analysis and Comparative Effectiveness Research Component of STOP 2
Cystic Fibrosis Foundation Therapeutics, Inc.
PI:   Kessler           Dates:    7/1/2018 - 6/30/2019

Nanotherm and Prostate Cancer - Phase I
MagForce USA, Inc.
PI:   Kessler           Dates:    7/1/2018 - 12/31/2019

PCORI IDIQ Task Order #12
Patient-Centered Outcomes Research Institute (PCORI)
PI:   Lavallee           Dates:    7/1/2018 - 4/30/2019

Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis
Seattle Children's Hospital Research Institute
PI:   Greenberg           Dates:    6/1/2018 - 5/31/2019

Practice Patterns and Impact of Operative and Non-operative Management of Diverticulitis
National Institutes of Health (NIH)
PI:   Flum           Dates:    5/1/2018 - 4/30/2019

Institute of Translational Health Sciences UL
National Center for Advancing Translational Sciences (NCATS)
PI:   Disis           Dates:    3/1/2018 - 2/28/2019

A new Nanotechnology Therapy for Glioblastoma and Prostate Cancer
MagForce USA, Inc.
PI:   Kessler           Dates:    2/1/2018 - 1/31/2019

Cost Effectiveness Analysis and Comparative Effectiveness Research Component of STOP 2
Cystic Fibrosis Foundation Therapeutics, Inc.
PI:   Kessler           Dates:    7/1/2017 - 6/30/2018

Institute of Translational Health Sciences
National Center for Advancing Translational Sciences (NCATS)
PI:   Disis           Dates:    6/1/2017 - 5/31/2022

Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis
Seattle Children's Hospital Research Institute
PI:   Greenberg           Dates:    6/1/2017 - 5/31/2018

Practice Patterns and Impact of Operative and Non-operative Management of Diverticulitis
National Institutes of Health (NIH)
PI:   Flum           Dates:    5/1/2017 - 4/30/2018

NKC - UW Center for Dialysis Innovation Grant
Northwest Kidney Centers (NKC)
PI:   Himmelfarb           Dates:    3/1/2017 - 7/31/2021

A new Nanotechnology Therapy for Glioblastoma and Prostate Cancer
MagForce USA, Inc.
PI:   Kessler           Dates:    2/1/2017 - 1/31/2018

A Pragmatic Trial of Lumbar Image Reporting with Epidemiology (LIRE)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
PI:   Jarvik           Dates:    1/1/2017 - 12/31/2017

Cost Effectiveness Analysis and Comparative Effectiveness Research Component of STOP 2
Cystic Fibrosis Foundation Therapeutics, Inc.
PI:   Kessler           Dates:    7/1/2016 - 12/31/2019

Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis
Seattle Children's Hospital Research Institute
PI:   Greenberg           Dates:    6/1/2016 - 5/31/2017

Institute of Translational Health Sciences (ITHS)
National Center for Advancing Translational Sciences (NCATS)
PI:   Disis           Dates:    6/1/2016 - 5/31/2017

Practice Patterns and Impact of Operative and Non-operative Management of Diverticulitis
National Institutes of Health (NIH)
PI:   Flum           Dates:    5/1/2016 - 4/30/2017

A Pragmatic Trial of Lumbar Image Reporting with Epidemiology
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
PI:   Jarvik           Dates:    1/1/2016 - 12/31/2016

Comparing Outcomes of Drugs and Appendectomy (CODA)
Patient-Centered Outcomes Research Institute (PCORI)
PI:   Flum           Dates:    10/1/2015 - 9/30/2020

Practice Patterns and Impact of Operative and Non-operative Management of Diverticulitis
National Institutes of Health (NIH)
PI:   Flum           Dates:    7/1/2015 - 6/30/2020

Topical Antibiotic Treatment for Spine Surgical Site Infections
National Institutes of Health (NIH)
PI:   Flum           Dates:    7/1/2015 - 6/30/2017

Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis
Seattle Children's Hospital Research Institute
PI:   Greenberg           Dates:    6/1/2015 - 5/31/2020

A Pragmatic Trial of Lumbar Image Reporting with Epidemiology (LIRE)
National Center for Complementary and Alternative Medicine (NCCAM)
PI:   Jarvik           Dates:    1/1/2014 - 12/31/2017

National Emphysema Treatment Trial

Collaborating on a cost-effectiveness study of a very controversial surgical treatment for emphysema patients.


CanCORS

Collaborating on studies of outcomes and patterns of care of both colorectal cancer and lung cancer. We are looking into what kinds of treatment certain types of patients receive and how we can improve the process of obtaining the best cancer care.


CISNET

Collaborating on a study focused on the tremendous increase in the rate of prostate cancer incidence during the 1990's. Much of this disease may represent 'overdiagnosis' which is accompanied by significant loss of quality of life in many cases.